Short Interest in Grifols, S.A. (NASDAQ:GRFS) Drops By 9.5%

Grifols, S.A. (NASDAQ:GRFS) saw a large decrease in short interest during the month of August. As of August 31st, there was short interest totalling 5,530,000 shares, a decrease of 9.5% from the August 15th total of 6,110,000 shares. Based on an average daily volume of 1,740,000 shares, the days-to-cover ratio is currently 3.2 days. Approximately 2.2% of the company’s stock are sold short.

Grifols Price Performance

Shares of Grifols stock traded down $0.34 during midday trading on Tuesday, reaching $8.90. 815,654 shares of the company’s stock traded hands, compared to its average volume of 2,133,314. Grifols has a 52 week low of $5.30 and a 52 week high of $12.15. The company’s 50 day simple moving average is $8.14 and its 200 day simple moving average is $7.28. The company has a quick ratio of 0.80, a current ratio of 1.68 and a debt-to-equity ratio of 1.06.

Grifols (NASDAQ:GRFS) last announced its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.21). The company had revenue of $1.96 billion during the quarter. Grifols had a return on equity of 1.73% and a net margin of 0.90%. Equities analysts forecast that Grifols will post 0.79 EPS for the current year.

Institutional Investors Weigh In On Grifols

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Cohen Investment Advisors LLC bought a new position in shares of Grifols in the first quarter valued at approximately $80,000. AQR Capital Management LLC acquired a new position in Grifols during the 2nd quarter worth $89,000. Cetera Advisors LLC bought a new stake in Grifols during the first quarter valued at about $147,000. China Universal Asset Management Co. Ltd. grew its position in shares of Grifols by 66.3% in the first quarter. China Universal Asset Management Co. Ltd. now owns 23,461 shares of the biotechnology company’s stock valued at $157,000 after purchasing an additional 9,350 shares during the last quarter. Finally, Morningstar Investment Services LLC acquired a new stake in shares of Grifols in the fourth quarter valued at about $186,000.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.